Stockscreener 앱 받기
125.59
0.22%
-0.28
시간 외 거래:
125.59
Gilead Sciences Inc 주식(GILD)의 최신 뉴스
Long term debt to total assets ratio of Gilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 Sh – BCBA:GILD.CI - TradingView
GILD Donates Antiviral Therapy to Support Ebola Response in Ugan - GuruFocus
Gilead donates remdesivir to Uganda for Ebola outbreak response - Investing.com
Gilead donates remdesivir to Uganda for Ebola outbreak response By Investing.com - Investing.com Canada
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief - Business Wire
UniSuper Management Pty Ltd Sells 124,258 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Vaughan David Investments LLC IL Invests $33.80 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Xponance LLC Has $29.15 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by Sector Gamma AS - MarketBeat
Swiss National Bank Has $417.34 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Te Ahumairangi Investment Management Ltd Sells 8,180 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Meiji Yasuda America Inc Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Nuveen LLC Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by DJE Kapital AG - MarketBeat
Aviva PLC Acquires 59,782 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Andra AP fonden Cuts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
SF: Rememberance Work Is Future Work: Gilead Commits $3M For Hiv/Aids Education And Preservation - SFGATE
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Gilead Sciences, Kite Pharma, Novartis, BMS, Allogene Therapeut - Barchart.com
Gilead Sciences Inc (GILD) Stock Up 3.6% but GF Value Says Overv - GuruFocus
Gilead (GILD) CMO Dietmar Berger converts RSUs and withholds shares for taxes - Stock Titan
Gilead (GILD) CFO exercises 2,796 RSUs and withholds 1,341 shares for taxes - Stock Titan
Gilead (NASDAQ: GILD) officer reports RSU vesting and tax withholding on Form 4 - Stock Titan
Gilead (GILD) CEO Daniel O'Day exercises RSUs and withholds shares for taxes - Stock Titan
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership - Gilead Sciences
Is Gilead (GILD) One of the Top Large Cap Value Stocks to Buy Now? - Insider Monkey
Gilead Sciences Target of Unusually Large Options Trading (NASDAQ:GILD) - MarketBeat
Gilead Sciences Inc Stock (GILD) Moved Up by 3.48% on Jun 11: Key Drivers Unveiled - TradingKey
Johnson Wealth Management LLC Makes New $2.51 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by Illinois Municipal Retirement Fund - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by LPL Financial LLC - MarketBeat
Cerity Partners LLC Buys 19,673 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline Development - Insider Monkey
Gilead Sciences Inc (GILD) Shares Fall 3.2% -- What GF Score of 76 Tells Investors - GuruFocus
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Gilead Sciences Inc Stock (GILD) Closed Down by 3.12% on Jun 10: What Investors Need To Know - TradingKey
Can Gilead Sciences HIV Franchise Drive Long-Term Growth? - Yahoo Finance
Motley Fool Asset Management LLC Buys 29,394 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Deutsche Bank AG Decreases Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by BLI Banque de Luxembourg Investments - MarketBeat
4th Circ. Revives Ex-Gilead Worker's Defamation Suit - Law360
What I Wish I Knew About Hepatitis B: Personal Journeys Out of Asia - Gilead Sciences
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study - Yahoo Finance
Gilead And Merck End Trodelvy-Keytruda Lung Cancer TrialGilead Sciences (NASDAQ:GILD), Merck & Co (NYS - Benzinga
Gilead Balances Trodelvy Setback With Once Weekly HIV Progress - simplywall.st
Gilead’s Mixed Trial News Puts HIV Progress And Oncology Risks In Focus - Yahoo Finance
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies - BioPharma Dive
Calamos Growth & Income Portfolio's Gilead Sciences Inc(GILD) Holding History - GuruFocus
Ex-Gilead Worker Lands New Shot at Defamation Suit Over Firing - Bloomberg Law News
Merck, Gilead score in effort to develop the first weekly HIV pill - Fierce Pharma
As Gilead's Trodelvy stumbles in first-line lung cancer, all eyes turn to Merck, AZ and Daiichi rivals - Fierce Pharma
Gilead and MSD’s once-weekly HIV pill meets primary endpoints in Phase III trials - Clinical Trials Arena
Merck, Gilead serve ‘sweet and sour’ spread after HIV win, cancer stumble - BioSpace
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $155 to $165 - Moomoo
Cantor Fitzgerald reiterates Gilead stock rating on HIV trial data By Investing.com - Investing.com South Africa
Merck and Gilead discontinue Phase III KEYNOTE-D46/EVOKE-03 study - The Pharma Letter
WINTON GROUP Ltd Sells 56,799 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Franklin Resources Inc. Sells 169,087 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead-MSD once-weekly oral HIV regimen meets Phase III endpoints - European Pharmaceutical Review
Gilead's lung cancer bid for Trodelvy hits wall, but HIV studies deliver better news - FirstWord Pharma
[Press release] Gilead and Merck announce positive topline results from two Phase 3 studies evaluating islatravir/lenacapavir, an oral once-weekly HIV treatment - European AIDS Treatment Group
Merck (MRK) and Gilead Sciences (GILD) Achieve Key Trial Milesto - GuruFocus
Merck, Gilead share positive phase 3 results from combination HIV pill - Seeking Alpha
Gilead and Merck’s Once-Weekly HIV Combo Pill Works in Trials - Bloomberg.com
Merck and Gilead discontinue lung cancer drug trial By Investing.com - Investing.com South Africa
Gilead and Merck’s once-weekly HIV pill meets trial goals - Investing.com
0.15%
0.18%
자본화:
|
볼륨(24시간):